Eylea demonstrating strong results at 2 years
MyVisionTest
neovascular AMD has shown sustained improvement in visual acuity at 96
weeks, Regeneron Pharmaceuticals and Bayer Healthcare announced in a
press release.
In the first year of the parallel VIEW 1 and VIEW 2 studies, patients
received Eylea (aflibercept, Regeneron Pharmaceuticals) injections of
either 0.5 mg every 4 weeks, 2 mg every 4 weeks or 2 mg every 8 weeks
after three initial monthly injections, compared with injections of
0.5 mg ranibizumab every 4 weeks, the release said.
In the second year, patients continued the same dosing regimen and
were evaluated each month to determine the need for re-treatment.
Minimum treatment frequency for all patients was 12 weeks.
At 96 weeks, the visual acuity gain for the group receiving
aflibercept every 8 weeks was 7.6 letters from baseline, compared with
8.4 letters at week 52, the release said. Those patients received an
average of 11.2 injections over 2 years, with an average of 4.2
injections in the second year.
Patients receiving ranibizumab saw a gain of 7.9 letters, compared
with 8.7 letters at week 52, according to the release. Those patients
received an average of 16.5 injections over 2 years, with a mean 4.7
injections in the second year.
"These second-year results confirm the sustainability of the vision
gains achieved by Eylea with a less-than-monthly dosing frequency,"
George D. Yancopoulos, MD, PhD, chief scientific officer of Regeneron
and president of Regeneron Laboratories, said in the release.
"Importantly, the second-year data demonstrated that for patients that
needed more anti-VEGF treatment, this was achieved with fewer
injections using Eylea."
OSN Supersite
http://www.osnsupersite.com/view.aspx?rid=90120
======================
ABOVE IS A PLAIN TEXT REPRODUCTION OF A NEWS STORY THAT APPEARS ON
MYVISIONTEST.COM. ANY HYPERLINKS, IMAGES, TABLES, OR OTHER
ENHANCEMENTS HAVE BEEN REMOVED. TO VIEW THE ORIGINAL VISIT THE BELOW
LINK.
http://www.myvisiontest.com/newsarchive.php?id=1352